Janssen Biotech Inc.
800 Ridgeview Drive
181 articles with Janssen Biotech Inc.
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
Alligator Bioscience Regains Global Rights From Janssen to CD40 Agonistic Antibody, ADC-1013 (JNJ-64457107)
Alligator Bioscience, announces that it has regained exclusive, worldwide rights from Janssen Biotech Inc.
7/31/2019The product was originally licensed in a partnership deal in 2015, which has now been terminated in what is being called a strategic portfolio decision by Janssen.
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
It was a big week for Alzheimer’s research as researchers from around the world descended on Los Angeles to attend the Alzheimer’s Association International Conference (AAIC) this week. Here's a look at some of the stories you may have missed.
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that its collaborator Janssen Biotech, Inc. (Janssen) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for the subcutaneous delivery of DARZALEX® (daratumumab) for patients with multiple myeloma.
Celsius Therapeutics Signs Collaboration Agreement with Janssen to Identify Response Biomarkers for Ulcerative Colitis
Celsius to Apply its Single-Cell Genomics and Machine Learning Platform at Unprecedented Scale in Large Phase 2 Clinical Study
Under the terms of the agreement, Celsius will use its single-cell genomics and machine learning platform to attempt to identify predictive biomarkers from Janssen’s VEGA Phase IIa clinical trial.
Darzalex in combination with lenalidomide and dexamethasone was approved as a first-line treatment for multiple myeloma patients who are ineligible for autologous stem cell transplant.
The agreement is the outcome of preclinical research on novel CD38 targeting concepts conducted by Genmab.
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
Alligator Bioscience, announces that Janssen Biotech, Inc. will present data from a Phase I clinical study of ADC-1013 at the upcoming ASCO Annual meeting held in Chicago on May 31- June 4.
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists
Protagonist Therapeutics, Inc. announced the expansion of its worldwide license and collaboration agreement with Janssen Biotech, Inc. for the co-development and commercialization of PTG-200, Protagonist's first-in-class, oral peptide IL-23 receptor antagonist, for all indications including inflammatory bowel disease (IBD).
US Bioservices Selected by Janssen as Single-Source Specialty Pharmacy Provider for BALVERSA™ (erdafitinib)
US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Janssen Biotech, Inc. (Janssen) to dispense BALVERSA™ (erdafitinib). Janssen received U.S. Food and Drug Administration (FDA) approval for BALVERSA™ on April 12, 2019
Therapeutic potential of Morphic pipeline expanded by inclusion of both integrin inhibitor and activator research
Waltham, Mass.-based Morphic Therapeutic and Janssen Biotech, a division of Johnson & Johnson, entered into a collaborative deal to develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.
Darzalex (daratumumab) for intravenous infusion is approved in the U.S. in combination with bortezomib, melphalan and prednisone for patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant.
MorphoSys AG announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute.
Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys AG announces that it was informed that in its lawsuit against Janssen Biotech and Genmab A/S, the United States (U.S.) District Court of Delaware has ruled in a Court Order on January 25, 2019, that the asserted claims of three MorphoSys patents with U.S. Patent Numbers 8,263,746, 9,200,061 and 9,758,590 are invalid.
No financial details of the agreement were released.